Immuron appoints mr. steven lydeamore as chief executive officer

Melbourne, australia, may 05, 2022 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the appointment of steven lydeamore as chief executive officer (ceo) of the company effective 27 june 2022.

IMRN Ratings Summary

IMRN Quant Ranking